Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP275569.RA5IeykZVg5acd6L1eNY7TnsE4l_RcS6FBY7kQ1Rbv-4E130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP275569.RA5IeykZVg5acd6L1eNY7TnsE4l_RcS6FBY7kQ1Rbv-4E130_assertion type Assertion NP275569.RA5IeykZVg5acd6L1eNY7TnsE4l_RcS6FBY7kQ1Rbv-4E130_head.
- NP275569.RA5IeykZVg5acd6L1eNY7TnsE4l_RcS6FBY7kQ1Rbv-4E130_assertion description "[Since the Bayer preparation is no longer available for treatment of large series of patients with ALL, the present study was designed to prospectively evaluate coagulation and fibrinolytic changes in leukaemic children receiving different doses of Medac ASP, which is now available for treatment of childhood ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP275569.RA5IeykZVg5acd6L1eNY7TnsE4l_RcS6FBY7kQ1Rbv-4E130_provenance.
- NP275569.RA5IeykZVg5acd6L1eNY7TnsE4l_RcS6FBY7kQ1Rbv-4E130_assertion evidence source_evidence_literature NP275569.RA5IeykZVg5acd6L1eNY7TnsE4l_RcS6FBY7kQ1Rbv-4E130_provenance.
- NP275569.RA5IeykZVg5acd6L1eNY7TnsE4l_RcS6FBY7kQ1Rbv-4E130_assertion SIO_000772 8857948 NP275569.RA5IeykZVg5acd6L1eNY7TnsE4l_RcS6FBY7kQ1Rbv-4E130_provenance.
- NP275569.RA5IeykZVg5acd6L1eNY7TnsE4l_RcS6FBY7kQ1Rbv-4E130_assertion wasDerivedFrom befree-20150227 NP275569.RA5IeykZVg5acd6L1eNY7TnsE4l_RcS6FBY7kQ1Rbv-4E130_provenance.
- NP275569.RA5IeykZVg5acd6L1eNY7TnsE4l_RcS6FBY7kQ1Rbv-4E130_assertion wasGeneratedBy ECO_0000203 NP275569.RA5IeykZVg5acd6L1eNY7TnsE4l_RcS6FBY7kQ1Rbv-4E130_provenance.